@article {Xu2020.03.18.20038513, author = {Yang Xu}, title = {Dynamic profile of severe or critical COVID-19 cases}, elocation-id = {2020.03.18.20038513}, year = {2020}, doi = {10.1101/2020.03.18.20038513}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {In December 2019, a cluster of acute respiratory illness, now known as SARS-CoV-2 pneumonia, occurred in Wuhan, China. World Health Organization (WHO) declared the rapidly spreading coronavirus outbreak a pandemic on March 11, 2020, acknowledging what has seemed clear for some time {\textemdash} the virus will likely spread to all countries on the globe. As of February 11, 2020, the Chinese Center for Disease Control and Prevention (China CDC) has officially reported that there are 2.0\% (889) asymptomatic cases, 2.3\% (1,023) death cases, and 80.9\% mild cases among 44,672 confirmed cases. 51.4\% (22,981) were male and 48.6\% (21,691) were female. Lymphopenia, in particular T lymphopenia, was common among patients with SARS-COV-2 in the observation. A notable drop in CD4 and CD8 lymphocyte counts occurred early in the course of the syndrome and was associated with adverse outcomes. The appearing a phenomenon of lymphocyte depletion (PLD) suggested severe adverse outcomes. The outcome observed: 60\% had discharged and 20\% had die.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeswe have all data referred to in the manuscript.}, URL = {https://www.medrxiv.org/content/early/2020/03/20/2020.03.18.20038513}, eprint = {https://www.medrxiv.org/content/early/2020/03/20/2020.03.18.20038513.full.pdf}, journal = {medRxiv} }